RT @hausmannMD: In patients with Sjogren's, Ianalumab, a dual-mode of action biologic combining BAFF receptor inhibition with B cell deplet…
Tweet Content
In patients with Sjogren's, Ianalumab, a dual-mode of action biologic combining BAFF receptor inhibition with B cell depletion, showed significant response in ESSDAI, a disease activity index, but did not seem to improve most PROs such as fatigue #ACR19 @RheumNow https://t.co/l5UFwOjt2C
Show on Archive Page
On
Display in Search Results
On